Juan Carlos Zapata
Director/Miembro de la Junta en BioMedx Group, Inc. .
Origen de la red de primer grado Juan Carlos Zapata.
Entidad | Tipo de entidad | Industria | |
---|---|---|---|
BioMedx Group, Inc.
BioMedx Group, Inc. Medical SpecialtiesHealth Technology BioMedx Group, Inc. operates as a medical technology company transforming the cosmetic surgery consultation services. The firm engages in product development focus on the modeling and simulation of the human face for aesthetic and facial reconstruction applications. The company was founded by Rudy A. Mazzocchi and is headquartered in Baltimore, MD.
1
| Private Company | Medical Specialties | 1 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Juan Carlos Zapata a través de su red personal
Empresa | Sector | Personas relacionadas | Puesto principal |
---|---|---|---|
Merck Serono SA
Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
Universität Konstanz | College/University | Doctorate Degree | |
Sanofi-Aventis Deutschland GmbH
Sanofi-Aventis Deutschland GmbH Pharmaceuticals: MajorHealth Technology Sanofi-Aventis Deutschland GmbH engages in the development, manufacture, and packaging of medicines, as well as pharmaceutical products. It also focuses on the research into the causes of diseases and the search for its drug treatment. The company was founded in 2004 and is headquartered in Frankfurt, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal | |
The Rockefeller University | College/University | Corporate Officer/Principal | |
Institut Pasteur
Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
REDX PHARMA PLC | Pharmaceuticals: Major | Director/Board Member | |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Biotechnology | Chairman | |
ENLIVEX THERAPEUTICS LTD. | Biotechnology | Director/Board Member | |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Medical/Nursing Services | Director/Board Member | |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Pharmaceuticals: Major | Director/Board Member | |
BioMed X GmbH
BioMed X GmbH Miscellaneous Commercial ServicesCommercial Services BioMed X GmbH is an independent research institute that conducts biomedical pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, and diagnostics. The private company is based in Heidelberg, Germany. The German company sponsors these projects with pharmaceutical partners such as Merck, Boehringer Ingelheim, Johnson & Johnson, AbbVie, and Roche. Talented early-career scientists from all over the world are recruited to work on these projects. The company combines crowdsourcing with local incubation to provide creative solutions to big biomedical research challenges. Each research team has access to state-of-the-art research infrastructure and is guided by experienced mentors from academia and industry. The company was founded in 2013 by Christian Tidona, who has been the CEO since 2013. | Miscellaneous Commercial Services | Director/Board Member | |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | Investment Managers | Consultant / Advisor |
Estadísticas
Internacional
Alemania | 6 |
Israel | 5 |
Suiza | 2 |
Estados Unidos | 2 |
Francia | 2 |
Sectorial
Health Technology | 9 |
Consumer Services | 3 |
Miscellaneous | 2 |
Health Services | 2 |
Commercial Services | 2 |
Operativa
Director/Board Member | 9 |
Corporate Officer/Principal | 3 |
Chairman | 2 |
Independent Dir/Board Member | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Las relaciones más conectadas
Insiders | |
---|---|
Bernhard Kirschbaum | 15 |
- Bolsa de valores
- Insiders
- Juan Carlos Zapata
- Conexiones Empresas